PIK3C2A and Hypercholesterolemia: The comprehensive safety profile of upadacitinib was favorable in accordance with RCTs, exhibiting the following most frequent AEs: hypercholesterolemia, increase in liver enzymes, acne, herpes simplex/zoster infection, anemia, plasma CPK elevation, and upper respiratory tract infection.